Clearmind Medicine INC. (CMND) — SEC Filings

Q: What are the key financial highlights for Clearmind Medicine INC.?

Key financial highlights for Clearmind Medicine INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: What is the investment thesis for CMND?

The investment thesis for CMND includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings filed by Clearmind Medicine INC..

Q: Who are the key executives at Clearmind Medicine INC.?

Key executives at Clearmind Medicine INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Clearmind Medicine INC. stock?

Risk factors for Clearmind Medicine INC. (CMND) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Clearmind Medicine INC.?

Forward-looking statements and predictions from Clearmind Medicine INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Clearmind Medicine INC.. Recent 6-K filing on Apr 21, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Clearmind Medicine INC. on SEC EDGAR

Overview

Clearmind Medicine INC. (CMND) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 15, 2026: Clearmind Medicine Inc. filed a Form 6-K on April 15, 2026, reporting a conversion agreement as an exhibit. The company, based in Vancouver, British Columbia, operates in the Pharmaceutical Preparations sector.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 16 bullish, 2 bearish, 32 neutral. The dominant filing sentiment for Clearmind Medicine INC. is neutral.

Filing Type Overview

Clearmind Medicine INC. (CMND) has filed 50 6-K with the SEC between Apr 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (50)

6-K Filing — 6-K · Apr 21, 2026
Clearmind Medicine Files 6-K with Conversion Agreement — 6-K · Apr 15, 2026 Risk: medium
Clearmind Medicine Inc. filed a Form 6-K on April 15, 2026, reporting a conversion agreement as an exhibit. The company, based in Vancouver, British Columbia, o
Clearmind Medicine Completes Preclinical Study for Alcohol Use Disorder Treatment — 6-K · Mar 30, 2026 Risk: medium
Clearmind Medicine Inc. announced on March 30, 2026, the successful completion of a preclinical study for its novel MEAI-based treatment for alcohol use disorde
Clearmind Medicine Files India Patent for Alcohol Use Disorder Drug — 6-K · Mar 27, 2026 Risk: medium
Clearmind Medicine Inc. filed a Form 6-K on March 27, 2026, reporting a patent application filed in India for its novel psychedelic compound CMND-101. This comp
6-K Filing — 6-K · Dec 31, 2025
Clearmind Medicine Reflects on 2025 Progress — 6-K · Dec 29, 2025 Risk: medium
Clearmind Medicine Inc. filed a Form 6-K on December 29, 2025, reporting on its activities for December 2025. The filing incorporates a press release dated Dece
6-K Filing — 6-K · Dec 16, 2025
6-K Filing — 6-K · Dec 12, 2025
6-K Filing — 6-K · Dec 10, 2025
Clearmind Medicine Fails Nasdaq Equity Rule — 6-K · Dec 5, 2025 Risk: high
Clearmind Medicine Inc. received a notification on November 3, 2025, from Nasdaq stating it is no longer in compliance with the Minimum Stockholders' Equity Rul
Clearmind Medicine Raises $1.6M in Direct Offering — 6-K · Dec 3, 2025 Risk: medium
On December 3, 2025, Clearmind Medicine Inc. entered into a securities purchase agreement for a registered direct offering. The company will sell 16,000,000 com
6-K Filing — 6-K · Dec 2, 2025
Clearmind Medicine Schedules Shareholder Meeting — 6-K · Nov 28, 2025 Risk: low
Clearmind Medicine Inc. filed a Form 6-K on November 28, 2025, providing proxy materials for its Annual and Special Meeting of Shareholders scheduled for Decemb
6-K Filing — 6-K · Nov 26, 2025
Clearmind Medicine Starts Patient Enrollment in Alcohol Use Disorder Trial — 6-K · Nov 25, 2025 Risk: medium
Clearmind Medicine Inc. announced on November 25, 2025, that it has initiated patient enrollment at Tel Aviv Sourasky Medical Center for its Phase I/IIa clinica
Clearmind Medicine Trial Continues After Safety Review — 6-K · Nov 24, 2025 Risk: medium
Clearmind Medicine Inc. announced on November 24, 2025, that its Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of its Phase I/II
Clearmind Medicine Expands Alcohol Use Disorder Trial — 6-K · Nov 20, 2025 Risk: medium
Clearmind Medicine Inc. announced on November 20, 2025, that it has activated a fifth global medical site for its FDA-approved clinical trial for alcohol use di
Clearmind Medicine Raises $2.185M in Direct Offering — 6-K · Nov 19, 2025 Risk: medium
On November 19, 2025, Clearmind Medicine Inc. entered into a securities purchase agreement to sell 10,925,000 common shares at $0.20 per share in a registered d
Clearmind Medicine Reports Positive Phase I/IIa Trial Results — 6-K · Nov 18, 2025 Risk: medium
Clearmind Medicine Inc. announced on November 18, 2025, positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for Alcoh
6-K Filing — 6-K · Nov 17, 2025
6-K Filing — 6-K · Nov 13, 2025
Clearmind Medicine Patent for Depression Treatment Published — 6-K · Nov 12, 2025 Risk: medium
Clearmind Medicine Inc. announced on November 12, 2025, that its patent application for a depression treatment has been published. This publication is a signifi
Clearmind Medicine Faces Nasdaq Delisting Risk — 6-K · Nov 6, 2025 Risk: medium
Clearmind Medicine Inc. received a notification from Nasdaq on November 6, 2025, indicating a deficiency in its minimum stockholders' equity. The company is req
Clearmind Expands IP for Depression Drug in South Korea — 6-K · Nov 5, 2025 Risk: medium
Clearmind Medicine Inc. announced on November 5, 2025, that it has expanded its intellectual property protection for its MEAI compound in South Korea. This expa
Clearmind Medicine Publishes US Patent App for MEAI Therapy — 6-K · Oct 31, 2025 Risk: medium
Clearmind Medicine Inc. announced on October 31, 2025, that it has advanced its fight against cocaine addiction with the publication of a U.S. patent applicatio
Clearmind Medicine Completes Phase I/IIa Trial Cohort — 6-K · Oct 30, 2025 Risk: medium
Clearmind Medicine Inc. announced on October 30, 2025, the completion of the first cohort treatment in its FDA-approved Phase I/IIa clinical trial for Alcohol U
Clearmind Medicine Appoints Chief of Global Impact — 6-K · Oct 27, 2025 Risk: medium
Clearmind Medicine Inc. announced on October 27, 2025, the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. This strategic hire aims to advance
Clearmind Medicine Completes Patient Enrollment for AUD Trial — 6-K · Oct 21, 2025 Risk: medium
Clearmind Medicine Inc. announced on October 21, 2025, that it has enrolled the final patient for the first cohort of its FDA-approved Phase I/IIa clinical tria
Clearmind Medicine Patent Targets Binge Disorders — 6-K · Oct 20, 2025 Risk: medium
Clearmind Medicine Inc. announced on October 20, 2025, the publication of a U.S. patent application. This application targets binge behavior disorders, potentia
Clearmind Medicine Convenes Inaugural Scientific Advisory Board — 6-K · Sep 25, 2025 Risk: medium
Clearmind Medicine Inc. announced on September 25, 2025, that it convened its inaugural Scientific Advisory Board meeting. This meeting is a key step in advanci
Clearmind Medicine Secures $10M for Strategic Opportunities — 6-K · Sep 19, 2025 Risk: medium
Clearmind Medicine Inc. announced on September 19, 2025, that it has entered into a Securities Purchase Agreement to secure $10 million. This funding is intende
Clearmind Medicine Secures Up to $10M Via Convertible Notes — 6-K · Sep 17, 2025 Risk: medium
On September 17, 2025, Clearmind Medicine Inc. entered into securities purchase agreements with institutional investors to issue and sell convertible promissory
Clearmind Medicine Files Interim Financials for July 31, 2025 — 6-K · Sep 11, 2025 Risk: medium
Clearmind Medicine Inc. filed its unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the periods ending
Clearmind Medicine Patents Obesity & Blood Sugar Therapy — 6-K · Aug 7, 2025 Risk: medium
Clearmind Medicine Inc. announced on August 7, 2025, the publication of an international patent application for a novel combination therapy designed to target o
Clearmind Medicine Gets IRB Approval for AUD Trial — 6-K · Aug 5, 2025 Risk: medium
Clearmind Medicine Inc. announced on August 5, 2025, that it has received Institutional Review Board (IRB) approval to commence a Phase 1/2a clinical trial for
Clearmind Medicine Files Patent for Weight Loss & Fatty Liver Therapy — 6-K · Jul 30, 2025 Risk: medium
Clearmind Medicine Inc. announced on July 30, 2025, that it has filed an international patent application for a novel combination therapy. This therapy is desig
Clearmind Medicine Updates Corporate Presentation — 6-K · Jul 29, 2025 Risk: low
Clearmind Medicine Inc. filed a Form 6-K on July 29, 2025, to report the posting of an updated corporate presentation on its website. This presentation is furni
Clearmind Expands Alcohol Use Trial — 6-K · Jul 15, 2025 Risk: medium
Clearmind Medicine Inc. announced on July 15, 2025, that it has expanded its clinical trial for alcohol use disorder by activating a new site and enrolling an a
Clearmind Medicine Gets IRB Approval for AUD Trial — 6-K · Jul 3, 2025 Risk: medium
Clearmind Medicine Inc. announced on July 3, 2025, that it has received Institutional Review Board (IRB) approval for a Phase 1/2a clinical trial. This trial wi
Clearmind Medicine Doses First Patient in Alcohol Use Disorder Trial — 6-K · Jun 30, 2025 Risk: medium
Clearmind Medicine Inc. announced on June 30, 2025, that it has dosed the first participant with its CMND-100 treatment in a clinical trial for Alcohol Use Diso
Clearmind Expands AUD Trial, Targets Multibillion-Dollar Market — 6-K · Jun 27, 2025 Risk: medium
Clearmind Medicine Inc. announced on June 27, 2025, that it is expanding its global clinical trial for its alcohol use disorder (AUD) treatment. This expansion
Clearmind Medicine Expands Alcohol Use Disorder Trial in Israel — 6-K · Jun 23, 2025 Risk: medium
Clearmind Medicine Inc. announced on June 23, 2025, that it has added a leading Israeli clinical site to its ongoing clinical trial for Alcohol Use Disorder. Th
Clearmind Medicine Hires Lobbying Firm for Psychedelic Drugs — 6-K · Jun 12, 2025 Risk: medium
Clearmind Medicine Inc. announced on June 12, 2025, that it has engaged a leading government and political affairs firm to advance its psychedelic therapeutics.
Clearmind Medicine Enrolls First Patient in Alcohol Use Disorder Trial — 6-K · Jun 5, 2025 Risk: medium
Clearmind Medicine Inc. announced on June 5, 2025, that it has enrolled the first patient in its Phase I/IIa clinical trial for a treatment targeting Alcohol Us
Clearmind Medicine Secures European Patent for Cocaine Addiction Therapy — 6-K · May 12, 2025 Risk: medium
Clearmind Medicine Inc. announced on May 12, 2025, that it has been granted a European Patent for its psychedelic-based combination therapy aimed at treating co
Clearmind Medicine Files International Patent for Eating Disorder Treatment — 6-K · Apr 25, 2025 Risk: medium
Clearmind Medicine Inc. filed a Form 6-K on April 25, 2025, to report the filing of an international patent application for a novel treatment of anorexia, bulim
Clearmind Medicine Starts Alcohol Use Disorder Trial — 6-K · Apr 23, 2025 Risk: medium
Clearmind Medicine Inc. announced on April 23, 2025, that it has successfully initiated its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) at all its
Clearmind Medicine Secures US Patent for Binge Behavior Treatment — 6-K · Apr 17, 2025 Risk: medium
Clearmind Medicine Inc. announced on April 17, 2025, that it has received a Notice of Allowance for a United States patent. This patent covers their novel appro
Clearmind Medicine Starts US Trial for Alcohol Use Disorder — 6-K · Apr 10, 2025 Risk: medium
Clearmind Medicine Inc. announced on April 10, 2025, the initiation of its first U.S. clinical site for the CMND-100 Phase 2b trial. This trial will evaluate CM
Clearmind Medicine Patents Next-Gen Psychedelics for Mental Health — 6-K · Apr 8, 2025 Risk: medium
Clearmind Medicine Inc. announced on April 8, 2025, the publication of an international patent application for its next-generation psychedelic compounds designe

Risk Profile

Risk Assessment: Of CMND's 41 recent filings, 1 were flagged as high-risk, 38 as medium-risk, and 2 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

Mary-Elizabeth Gifford

Top Tags

clinical-trial (15) · pharmaceuticals (12) · drug-development (12) · healthcare (12) · patent (10) · pharmaceutical (5) · alcohol-use-disorder (3) · foreign-private-issuer (3) · sec-filing (3) · capital-raise (3)

Key Numbers

Nasdaq Rule: 5550(b)(1) — This is the specific rule Clearmind Medicine is not in compliance with.
Gross Proceeds: $1.6M — Raised from the sale of 16,000,000 common shares at $0.10 each in a registered direct offering.
Common Shares Sold: 16,000,000 — Offered and sold in a registered direct offering at $0.10 per share.
Price Per Share: $0.10 — The price at which common shares were sold in the registered direct offering.
Shares Sold: 10,925,000 — Number of common shares sold in the offering.
Compliance Period: 180 days — The timeframe Clearmind Medicine has to rectify its stockholders' equity deficiency.
Securities Purchase Agreement: $10 million — Funds secured to explore strategic opportunities.
Convertible Promissory Notes: $10.0M — Maximum aggregate principal amount the company can raise through the sale of notes.
Alcohol Use Disorder Market Size: $multibillion — Indicates the significant commercial potential of Clearmind's treatment.

Frequently Asked Questions

What are the latest SEC filings for Clearmind Medicine INC. (CMND)?

Clearmind Medicine INC. has 50 recent SEC filings from Apr 2025 to Apr 2026, including 50 6-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CMND filings?

Across 50 filings, the sentiment breakdown is: 16 bullish, 2 bearish, 32 neutral. The dominant sentiment is neutral.

Where can I find Clearmind Medicine INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Clearmind Medicine INC. (CMND) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Clearmind Medicine INC.?

Financial highlights for Clearmind Medicine INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for CMND?

Investment thesis data for CMND will be available once enriched filings are processed.

Who are the key executives at Clearmind Medicine INC.?

Key executives identified across Clearmind Medicine INC.'s filings include Mary-Elizabeth Gifford.

What are the main risk factors for Clearmind Medicine INC. stock?

Of CMND's 41 assessed filings, 1 were flagged high-risk, 38 medium-risk, and 2 low-risk.

What are recent predictions and forward guidance from Clearmind Medicine INC.?

Forward guidance and predictions for Clearmind Medicine INC. are extracted from SEC filings as they are enriched.